Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
Bristol-Myers Squibb
Posted inClinical Trials, In the Pipeline, Oncology, Regulatory
Small Cell Lung Cancer: Let Immunotherapy Help!
A deadly disease and modern pharmacological attempts to treat it.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis
Siponimod released by Novartis is an improved version of Gilenya.
